Financial Performance - Mirion's Q2 2025 revenue reached $222.9 million, reflecting a 7.6% total increase, including a 5.4% organic growth compared to Q2 2024[11] - Adjusted EBITDA for Q2 2025 was $51.2 million, a 4.9% increase compared to Q2 2024, with the Medical segment's margin expansion offsetting impacts in the Nuclear & Safety segment[11] - Adjusted Free Cash Flow generation for Q2 was +$6 million, with $35 million generated Year-To-Date (YTD), representing a 35% YTD conversion rate[11] - Adjusted diluted EPS increased by 10% to $0.11, excluding impacts from warrants, founders' shares, and convertible notes, reaching $0.13 per share[36] Orders and Backlog - Total orders increased by 1.6% in Q2 2025 compared to Q2 2024, driven by higher orders in the Medical segment, while the Nuclear & Safety segment faced a tough comparison and timing impacts[11] - The company anticipates accelerating order rates in the second half of 2025[23] - The backlog reached $825 million, a 10.2% increase compared to adjusted Q2 2023 and a 1.9% increase compared to adjusted Q2 2024[60] Segment Performance - Nuclear & Safety segment revenue increased by 5.8% to $141.7 million in Q2 2025, with 2.9% organic growth[39] - Medical segment revenue increased by 10.9% to $81.2 million in Q2 2025, with 10.1% organic growth[46] Strategic Initiatives and Outlook - Mirion successfully completed a $400 million convertible note offering and refinanced its Term Loan B, improving its capital structure[12] - The company updated its 2025 guidance, projecting organic revenue growth of 5.0-7.0% and total revenue growth of 7.0-9.0%, including an FX tailwind of approximately 125 basis points and acquisition-related tailwind of approximately 100 basis points[55] - The company expects Adjusted EBITDA to be in the range of $223-$233 million, with a margin of 24.0-25.0%, and Adjusted Free Cash Flow to be in the range of $95-$115 million, representing a 43-49% conversion rate[55]